Immatics N.V. Warrants

$2.82
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-1.05%) Today
$0.00 (0.00%) As of 9:00 PM UTC after-hours

Why Robinhood?

You can watch IMTXW and buy or sell other stocks, options, and ETFs commission-free!

About IMTXW

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCERâ„¢). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany. The listed name for IMTXW is Immatics N.V. Warrants.

CEO
Harpreet Singh-Jasuja, PhD
Employees
—
Headquarters
Tuebingen, Baden Wuerttemberg
Founded
2020
Market Cap
—
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
17.75K
High Today
$2.85
Low Today
$2.71
Open Price
$2.80
Volume
10.50K
52 Week High
$8.49
52 Week Low
$2.29

Collections

You May Also Like

DWSH
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure